|
Evaluation of astaxanthin effects on the survival and proliferation of human adipose derived stem cells
|
Nazem Ghasemi   |
| Department of Anatomical Science and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , n_ghasemi@med.mui.ac.ir |
|
|
Abstract: (4326 Views) |
Background and Aim: In order to enhance in vivo stem cell viability and considering similar anti-inflammatory and anti-apoptotic effects of human adipose derived stem cells (hADSCs) and astaxanthin (AST) and their ability to cross the blood-brain barrier, we investigated the effects of (AST) on hADSCs proliferation and viability to provide a supplement for cell based therapy in MS patients.
Materials and methods: After isolation of hADSCs and assessment of CD markers, they were cultured in DMEM-F12 medium in the presence of AST at various concentrations (1, 5, and 10 ng/ml) for 72 h. Finally, we assessed cell proliferation and cell viability by MTT and Tryphan Blue methods.
Results: The results revealed that a high percentage of hADSCs expressed CD90 and CD44 markers and a low percentage of them expressed hematopoietic cell markers. In addition, in the group cultured in the presence of 5 ng/ml AST the mean percentage of cell viability increased significantly compared to other groups (p = 0.04). Tryphan Blue results also revealed significant effect of AST on stem cell proliferation and culture of these cells in the presence of 5 ng/ml of AST, led to significant increase in the mean percentage of cell count compared to the results of the control group (p = 0.03).
Conclusion: Astaxanthin can increase hADSCs proliferation and survival and this agent can be used in the cell-based therapies in MS patients.
Key words: Astaxanthin, Cell proliferation, Cell survival.
Received: Apr 18, 2017 Accepted: Jul 15, 2017 |
|
| Keywords: Astaxanthin, Cell proliferation, Cell survival. |
|
|
Full-Text [PDF 261 kb]
(1007 Downloads)
|
Type of Study: Original Research |
Subject:
General
Received: 2017/11/21 | Accepted: 2017/11/21 | Published: 2017/11/21
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
